BioCentury (@BioCentury) header
BioCentury (@BioCentury) profile picture

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: https://teapaw.org/t.co/V33Z1gfUfZ

Redwood City, Calif.
Joined December 2010
Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)Photo by BioCentury (@BioCentury)
In BioCentury's Finance Report: Flagship's new UK origination lab, VCs back VitriVax's Lyme disease program; rounds for Isomorphic, Marrow and Seawolf; Sellas' follow-on; and more buff.ly/D6zLaKf
1
1
517
Neutrophil extracellular traps can protect against infection or drive tissue damage. Five studies in BioCentury’s Innovation Radar explore ways to suppress harmful NET activity — and the risks of compromising antimicrobial defense. buff.ly/mlBzQtp
2
4
561
Medicare buy-ins for older adults and guaranteed coverage for children could bring the U.S. closer to universal coverage. In a Guest Commentary, former Gore policy adviser David Beier makes the case for incremental reform over a single-payer overhaul. buff.ly/fw6OKBE
481
Seawolf Therapeutics emerged from stealth with $100M to develop DNA-LNP therapies designed to combine the durability of viral gene therapies with the repeat dosing possible with RNA-LNPs. An Emerging Company Profile by BioCentury's @DanielleGolovin buff.ly/lhIxAha
2
3
589
ai3Bio: Resetting the immune system with in vivo T cell depletion. Merging complementary LNP-mRNA and mAb-based approaches targeting Th17 cells for autoimmune diseases, backed by a $48M series A buff.ly/P9A7cWu
1
3
562
Isomorphic raises $5B in the largest biotech venture round yet. AI drug design company’s series C round comes just six months after a $2.1B round, and before a program has entered the clinic. buff.ly/Tw7bj66
1
1
5
663
Biopharmas should invest in tools to close biological AI’s data gaps — a Perspective by BioCentury's Lindsay Martin. Shared initiatives can set the foundation, but biopharmas should invest in measurements that address gaps relevant to their portfolios buff.ly/Rc9YTRM
1
1
613
FDA held Summit to its survival bar for ivonescimab in EGFR-mutant lung cancer. The pivotal trial met its PFS endpoint but missed on overall survival. Longer follow-up showed a similar survival trend favoring ivonescimab in Western and Asian patients. buff.ly/264hJ3j
1
3
682
BIO’s plan for ‘securing America’s biotech century’: Trade group trying to use China as a fulcrum to advance policies to enhance U.S. competitiveness buff.ly/3S8Fwes
1
879
China’s innovation moment sees a rise in first in class: BioCentury's Simone Fishburn & Lindsay Martin's scene setter analysis for BioCentury-BayHelix China Healthcare Summit 2026 buff.ly/3Mmv7E2
2
733